Result of EGM

RNS Number : 4691I

Oxford Biomedica PLC

25 July 2012

 

FOR IMMEDIATE RELEASE

25 July 2012

OXFORD BIOMEDICA PLC

GENERAL MEETING

Oxford, UK - 25 July 2012: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, announced today that all resolutions proposed were duly passed at its General Meeting, held today in London.

In accordance with Listing Rule 9.6.18, the following resolution passed at the meeting concerned special business:

·      Resolution 2: to empower the Directors to allot equity securities for cash, pursuant to section 570 of the Act as if section 561 of the Act did not apply to such allotment, up to an aggregate nominal amount of £6,410,373.53.

The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Company's website at www.oxfordbiomedica.co.uk (located on pages 143 to 145 of the prospectus dated 6 July 2012).

Certified copies of the document setting out the above resolutions passed at this General Meeting have been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.Hemscott.com/nsm.do.

The results of the proxy voting in advance of the meeting are shown below.

Resolution	Votes  For	Votes at  Chairman's Discretion	Votes at  other proxy Discretion	Votes Against	Votes  Withheld	Total votes cast	Result
Ordinary resolution
1	435,386,160	607,230	1,441,423	251,913	40,343	437,727,069	Passed
Special resolution
2	435,168,275	599,040	1,441,423	339,017	179,314	437,727,069	Passed
Ordinary resolution
3	435,324,264	602,092	1,441,423	255,979	103,311	437,727,069	Passed

-Ends-

For further information, please contact:
Oxford BioMedica plc: Lara Mott, Head of Corporate Communications	Tel: [phone]
Media Enquiries: Mary Clark/Sarah Macleod/Claire Dickinson M:Communications	Tel: [phone]

Notes to editors

1. Oxford BioMedica

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs.  The Company's technology platform includes a highly efficient LentiVector^® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy.  Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb.  Further information is available at www.oxfordbiomedica.co.uk.

 

END

 

 

REGSELFSIFESEDW